FindTrial
Sign In

Long term opioid administration in oncologic chronic pain: open label, prospective study on efficacy, safety and pharmacogenetic factors. - ND

Long term opioid administration in oncologic chronic pain: open label, prospective study on efficacy, safety and pharmacogenetic factors. - ND

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2008-002273-12-IT
Enrollment
Unknown
Registered
2008-05-21
Start date
2008-06-23
Completion date
Unknown
Last updated
2015-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oncologic chronic pain MedDRA version: 9.1 Level: LLT Classification code 10058019 Term: Cancer pain

Interventions

Trade Name: ORAMORPH*OS SOL FL 120ML 20MG/ Pharmaceutical Form: Oral solution INN or Proposed INN: Morphine Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration nu

Sponsors

OSPEDALE POLICLINICO S. MATTEO
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: age > 18 years, oncologic, chronic, neurophatic and/or nocicettive periferic pain Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: abuse history, opioid analgesic use history, opioid allergies, ...

Design outcomes

Primary

MeasureTime frame
Main Objective: -to identify opioid product with the best clinical-pharmacological efficacy-safety profile -to identify genetic polymorphism relatied to the best clinical response.;Secondary Objective: to evaluate opioid pharmacokinetic;Primary end point(s): pain reduction at least 40% in VAS scale—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026